Evidence map›Paper›PMID 41741470›Full record

ArticleNature communications2026

ERCC6L2 ensures repair fidelity for staggered-end DNA double-strand breaks.

Eric J Aird, Almudena Serrano-Benitez, Sebastian M Siegner, Elda Cannavo, Rimma Belotserkovskaya, Nadia Gueorguieva, John Fielden, Grégoire Cullot, Sandra Ammann, Aldo S Bader and 8 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Eric J Aird *Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-4873-042X
Almudena Serrano-Benitez *Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-7263-6863
Sebastian M Siegner *Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-6811-0474
Elda CannavoInstitute for Research in Biomedicine, Università della Svizzera italiana (USI), Faculty of Biomedical Sciences, Bellinzona, Switzerland.
Rimma BelotserkovskayaCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Nadia GueorguievaCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
John FieldenDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Grégoire CullotDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Sandra AmmannInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0003-0385-1890
Aldo S BaderCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Vipul GuptaThe Gurdon Institute, University of Cambridge, Cambridge, UK.
Geoffroy AndrieuxInstitute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-5389-9481
Rebecca RaabInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0009-0002-4743-057X
Mónica Del Rey GonzálezInstituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (CIC), Salamanca, Spain.
Toni CathomenInstitute for Transfusion Medicine and Gene Therapy, Medical Center - University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0002-7757-4630
Petr CejkaInstitute for Research in Biomedicine, Università della Svizzera italiana (USI), Faculty of Biomedical Sciences, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-9087-032X
Jacob E CornDepartment of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland. jacob.corn@biol.ethz.ch.ORCID http://orcid.org/0000-0002-7798-5309
Stephen P JacksonCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. Steve.Jackson@cruk.cam.ac.uk.ORCID http://orcid.org/0000-0001-9317-7937

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 855741-DDREAMM-ERC-2019-SyGEC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 855741-DDREAMM-ERC-2019-SyG
6 · The paper itself

Abstract

DNA double-strand breaks (DSBs) both pose threats to genome integrity and are commonly used for genome editing applications. Structural features of DSB ends play key roles in determining DNA repair pathway usage and outcomes during genome editing, but the cellular factors involved in these processes are only partially known. Through genome-wide CRISPRi screening, we identify ERCC6L2 as critical for repairing Cas12a-induced staggered DSBs but irrelevant for Cas9-induced blunt DSBs. We show that ERCC6L2 acts as a protection factor for staggered DSBs with either 5' or 3' polarity, preventing large deletions and translocations stemming from DNA damage induced by Cas12a, TALENs, or dual Cas9 nicks. Furthermore, ERCC6L2 loss hyper-sensitizes cells to multiple staggered DSBs induced by promiscuous Cas12a activity or etoposide-induced TOP2 trapping. By combining genetics and biochemical reconstitution, we find that ERCC6L2 counteracts MRE11-RAD50-NBS1 (MRN)-mediated resection by binding and melting staggered DNA ends, thereby promoting accurate end joining. Our data reveal a protective role of ERCC6L2 in staggered-end DSB repair, which suggests the molecular underpinnings of pathology in patients with ERCC6L2 mutations and cautions against using overhang-inducing genome editing tools for their treatment.

Indexed as

DNA Breaks, Double-StrandedDNA HelicasesDNA RepairPoly-ADP-Ribose Binding ProteinsBacterial ProteinsCell Cycle ProteinsCRISPR-Associated ProteinsCRISPR-Cas SystemsDNA-Binding ProteinsDNA End-Joining RepairEndodeoxyribonucleasesEtoposideGene EditingHEK293 CellsHumansMRE11 Homologue ProteinBacterial ProteinsCas12a proteinCell Cycle ProteinsCRISPR-Associated ProteinsDNA-Binding ProteinsDNA HelicasesEndodeoxyribonucleasesERCC6L2 protein, humanEtoposideMRE11 Homologue ProteinMRE11 protein, humanNBN protein, humanNuclear ProteinsPoly-ADP-Ribose Binding Proteins

Identifiers

PMID41741470
PMCPMC13013651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.